Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of the Combination of Vismodegib GDC-0449 and Erlotinib +/- Gemcitabine

NCT00878163 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00878163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00878163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of the Combination of Vismodegib GDC-0449 and Erlotinib +/- Gemcitabine
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 31, 2009
Completion date
March 6, 2027
Enrollment
55 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

adult solid neoplasm, pancreatic acinar cell carcinoma, pancreatic ductal adenocarcinoma, recurrent pancreatic carcinoma, stage iv pancreatic cancer ajcc v6 and v7